- Report
- October 2024
- 185 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 194 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2025
- 183 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- May 2024
- 181 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- April 2024
- 38 Pages
Global
From €3798EUR$3,995USD£3,191GBP
- Report
- March 2025
- 142 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- April 2023
- 118 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- June 2020
- 114 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- November 2022
- 288 Pages
Global
From €3422EUR$3,600USD£2,875GBP
- Report
- February 2024
- 105 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- December 2022
- 34 Pages
Global
From €1901EUR$2,000USD£1,597GBP

Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that is resistant to many antibiotics. As a result, it is a major cause of infections in hospitals and other healthcare settings. To combat this, the MRSA drug market has developed a range of treatments, including antibiotics, antiseptics, and vaccines. These drugs are designed to target the bacteria and reduce the risk of infection.
The MRSA drug market is highly competitive, with a range of companies offering different treatments. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. These companies are constantly developing new treatments to combat the spread of MRSA and other infectious diseases. Show Less Read more